Effect of implanted sustain-released 5-fluorouracil during operation in patients with advanced rectal cancer
10.3760/cma.j.issn.1008-6315.2011.04.030
- VernacularTitle:进展期直肠癌术中植入氟尿嘧啶缓释剂的疗效观察
- Author:
Ling DAI
;
Xiaolin TIAN
;
Xiao CHEN
- Publication Type:Journal Article
- Keywords:
Rectal Cancer;
Intraperitoneal Chemotherapy;
5-Fluorouracil;
Sustain-released Agent
- From:
Clinical Medicine of China
2011;27(4):430-433
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the effect of intraperitoneal interstitial implant of Sustained-release 5-Fluorouracil during operation for advanced rectal cancer. Methods One hundred and four cases with advanced rectal cancer were enrolled into the study and divided into 3 groups: treatment group 1(n = 37), underwent combined hypotonic peritoneal chemo-hyperthermia and Sustain-released 5-fluorouracil implantation treatment during operation; treatment group 2(n = 34), underwent combined intraoperative hypotonic peritoneal chemohyperthermia and early postoperatively intraperitoneal chemotherapy treatment; and control group(n = 33),underwent peritoneal lavage during radical resection alone. Results Digestive tract toxicity in group 1 was significantly lower than that in group 2(2. 70% vs. 20. 59%, x2 = 9. 104, P ＜ 0. 05). There were significant difference on 1 year survival rate among the three groups. The 2-year survival rate of group 1 was significantly higher than that in the control group (78. 37% vs. 48. 48%, x2 = 1. 297 ,P ＜ 0. 05). After two years follow-up the 2-year local recurrence rate of group 1 was significantly lower than that in the control group(21.62% vs 32. 35 %, x2 = 7. 001, P ＜ 0. 05). However, no significant difference was found compared to group 2, which was 32. 35%. Conclusion lntraperitoneal interstitial implant of Sustain-released 5-Fluorouracil during operation is an effective intraperitoneal chemotherapy with mild side effects for advanced rectal cancer.
